Beta-2-receptor regulation of immunomodulatory proteins in airway smooth muscle

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Airway smooth muscle (ASM) cells have been shown to secrete significant amounts of immunomodulatory factors (IMFs), many of which are typically ascribed to trafficking leukocytes (e.g., GM-CSF, IL-6, IL-13, and eotaxin), and may be indicative of an immunomodulatory role for ASM in control of airway function, as well as in airway diseases states associated with acute and/or chronic inflammation, such as asthma and COPD. Furthermore, epinephrine analogues such as albuterol, which ligate the G-protein coupled beta-2- receptor and have been clinically applied to promote ASM relaxation and bronchodilation in the treatment of asthma and COPD, also have been reported to downregulate IMF release by ASM, both individually and in additive fashion, in combination with corticosteroids. Based on experimental data, an inverse agonist/agonist model is proposed to explain these behaviors modeled on cell stimulatory states and G-protein coupled receptor activation. The ramifications of the model are considered in light of unexplained paradoxical clinical findings, and may provide a model for the understanding of beta-2-receptor agonist modulation of airway inflammation and function.

Original languageEnglish (US)
Pages (from-to)643-654
Number of pages12
JournalFrontiers in Bioscience - Scholar
Volume3 S
Issue number2
StatePublished - Jan 1 2011

Fingerprint

Smooth Muscle
Muscle
Chronic Obstructive Pulmonary Disease
CCR10 Receptors
Asthma
Inflammation
Proteins
Muscle Relaxation
Airway Management
Interleukin-13
Albuterol
Granulocyte-Macrophage Colony-Stimulating Factor
G-Protein-Coupled Receptors
Epinephrine
Smooth Muscle Myocytes
Interleukin-6
Adrenal Cortex Hormones
Leukocytes
Down-Regulation
GTP-Binding Proteins

Keywords

  • (R)-Albuterol
  • (S)- Albuterol
  • Albuterol
  • Antagonist
  • Beta- Receptor
  • Beta-Arrestin
  • Formoterol
  • GM-CSF
  • Inverse Agonism
  • Levalbuterol
  • Ligand
  • Racemic Mixture
  • Review

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)
  • Medicine(all)

Cite this

Beta-2-receptor regulation of immunomodulatory proteins in airway smooth muscle. / Ameredes, Bill.

In: Frontiers in Bioscience - Scholar, Vol. 3 S, No. 2, 01.01.2011, p. 643-654.

Research output: Contribution to journalArticle

@article{a8fb1f92194046cf9ee599e255fe6d58,
title = "Beta-2-receptor regulation of immunomodulatory proteins in airway smooth muscle",
abstract = "Airway smooth muscle (ASM) cells have been shown to secrete significant amounts of immunomodulatory factors (IMFs), many of which are typically ascribed to trafficking leukocytes (e.g., GM-CSF, IL-6, IL-13, and eotaxin), and may be indicative of an immunomodulatory role for ASM in control of airway function, as well as in airway diseases states associated with acute and/or chronic inflammation, such as asthma and COPD. Furthermore, epinephrine analogues such as albuterol, which ligate the G-protein coupled beta-2- receptor and have been clinically applied to promote ASM relaxation and bronchodilation in the treatment of asthma and COPD, also have been reported to downregulate IMF release by ASM, both individually and in additive fashion, in combination with corticosteroids. Based on experimental data, an inverse agonist/agonist model is proposed to explain these behaviors modeled on cell stimulatory states and G-protein coupled receptor activation. The ramifications of the model are considered in light of unexplained paradoxical clinical findings, and may provide a model for the understanding of beta-2-receptor agonist modulation of airway inflammation and function.",
keywords = "(R)-Albuterol, (S)- Albuterol, Albuterol, Antagonist, Beta- Receptor, Beta-Arrestin, Formoterol, GM-CSF, Inverse Agonism, Levalbuterol, Ligand, Racemic Mixture, Review",
author = "Bill Ameredes",
year = "2011",
month = "1",
day = "1",
language = "English (US)",
volume = "3 S",
pages = "643--654",
journal = "Frontiers in Bioscience - Scholar",
issn = "1945-0516",
publisher = "Frontiers in Bioscience",
number = "2",

}

TY - JOUR

T1 - Beta-2-receptor regulation of immunomodulatory proteins in airway smooth muscle

AU - Ameredes, Bill

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Airway smooth muscle (ASM) cells have been shown to secrete significant amounts of immunomodulatory factors (IMFs), many of which are typically ascribed to trafficking leukocytes (e.g., GM-CSF, IL-6, IL-13, and eotaxin), and may be indicative of an immunomodulatory role for ASM in control of airway function, as well as in airway diseases states associated with acute and/or chronic inflammation, such as asthma and COPD. Furthermore, epinephrine analogues such as albuterol, which ligate the G-protein coupled beta-2- receptor and have been clinically applied to promote ASM relaxation and bronchodilation in the treatment of asthma and COPD, also have been reported to downregulate IMF release by ASM, both individually and in additive fashion, in combination with corticosteroids. Based on experimental data, an inverse agonist/agonist model is proposed to explain these behaviors modeled on cell stimulatory states and G-protein coupled receptor activation. The ramifications of the model are considered in light of unexplained paradoxical clinical findings, and may provide a model for the understanding of beta-2-receptor agonist modulation of airway inflammation and function.

AB - Airway smooth muscle (ASM) cells have been shown to secrete significant amounts of immunomodulatory factors (IMFs), many of which are typically ascribed to trafficking leukocytes (e.g., GM-CSF, IL-6, IL-13, and eotaxin), and may be indicative of an immunomodulatory role for ASM in control of airway function, as well as in airway diseases states associated with acute and/or chronic inflammation, such as asthma and COPD. Furthermore, epinephrine analogues such as albuterol, which ligate the G-protein coupled beta-2- receptor and have been clinically applied to promote ASM relaxation and bronchodilation in the treatment of asthma and COPD, also have been reported to downregulate IMF release by ASM, both individually and in additive fashion, in combination with corticosteroids. Based on experimental data, an inverse agonist/agonist model is proposed to explain these behaviors modeled on cell stimulatory states and G-protein coupled receptor activation. The ramifications of the model are considered in light of unexplained paradoxical clinical findings, and may provide a model for the understanding of beta-2-receptor agonist modulation of airway inflammation and function.

KW - (R)-Albuterol

KW - (S)- Albuterol

KW - Albuterol

KW - Antagonist

KW - Beta- Receptor

KW - Beta-Arrestin

KW - Formoterol

KW - GM-CSF

KW - Inverse Agonism

KW - Levalbuterol

KW - Ligand

KW - Racemic Mixture

KW - Review

UR - http://www.scopus.com/inward/record.url?scp=79955967007&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955967007&partnerID=8YFLogxK

M3 - Article

VL - 3 S

SP - 643

EP - 654

JO - Frontiers in Bioscience - Scholar

JF - Frontiers in Bioscience - Scholar

SN - 1945-0516

IS - 2

ER -